Although investors often think of genetic testing as a single market, that’s not quite true. There are multiple market verticals that each require unique technology, commercial infrastructure, and regulatory oversight. Similarly, investors often think of genomics as the singular opportunity, but the most successful companies will take a multi-omics approach by combining genomics, transcriptomics, proteomics, and more.

7investing Lead Advisor Maxx Chatsko’s September 2021 recommendation is and will continue to be a leader in molecular testing. The company has strategically built out its technology stack in recent years, which sets the stage for significant long-term growth in market verticals worth more than $60 billion — it just has to execute.

Transcript

Forget genomics! Start thinking in terms of multi-omics.

Hey everyone, I’m 7investing Lead Advisor Maxx Chatsko. I cover biotechnology and renewable energy here at 7investing, where we empower you to invest in your future by giving you our seven best stock market opportunities each and every month, each backed by the domain competence of one of our lead advisors.

My recommendation for September 2021 is building out an impressive technology stack for our multi-omics future. “What the heck does that mean, Maxx? I thought genomics is the future?” Well, that’s not quite the best way to think about it.

There’s an Indian parable about three blind men encountering an elephant for the first time. One grabs the trunk, one is feeling an ear, and the other is feeling the elephant’s hide. Afterwards, each is confident he can explain what an elephant looks like. Of course, none of them have all the information they need.

Our current approach to health and disease works in a very similar way. If you’re only looking at genomics (the DNA), then you only have one molecular signal. To get the most accurate understanding, you need to incorporate other molecular signals into a single product. That could include RNA, or transcriptomics. That could include proteins, or proteomics. Sometimes that includes chemical modifications to DNA, or epigenomics. There are a lot of omics out there!

My point is, we increasingly need to combine multiple molecular signals to get the best, most complete understanding of health and disease. This is what it means to take a multi-omics approach — and my recommendation this month is doing just that. If you want to read my full research report, then go to 7investing.com. And remember, it’s never too early or too late to start investing in your future.